Scarica l'app Stockscreener
14.42
0.31%
0.13
Precedente Chiudi:
$14.55
Aprire:
$14.8
Volume 24 ore:
42,578
Relative Volume:
0.09
Capitalizzazione di mercato:
$1.00B
Reddito:
$62.71M
Utile/perdita netta:
$-112.51M
Rapporto P/E:
5.15
EPS:
2.8
Flusso di cassa netto:
$-96.01M
1 W Prestazione:
-10.24%
1M Prestazione:
+10.82%
6M Prestazione:
+63.80%
1 anno Prestazione:
+77.55%
Intervallo 1D:
$14.33
$15.00
Intervallo di 1 settimana:
$14.43
$16.24
Portata 52W:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ZYME | 14.34 | 1.00B | 62.71M | -112.51M | -96.01M | 2.80 |
| VRTX | 449.15 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.91 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.52 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga
Zymeworks to Showcase Innovations at Investor Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Zymeworks to Present at Major Healthcare Conferences, Announces R&D Day for Pipeline Updates | ZYME Stock News - StockTitan
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for - GlobeNewswire
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) - GlobeNewswire Inc.
Leerink Partners Upgrades Zymeworks (ZYME) - MSN
Redmile Group, LLC Adjusts Stake in Zymeworks Inc - GuruFocus.com
Zymeworks stock soars to 52-week high, hits $17.29 By Investing.com - Investing.com Australia
Zymeworks stock soars to 52-week high, hits $17.29 - Investing.com India
Zymeworks (NYSE:ZYME) Stock Rating Upgraded by Leerink Partners - Defense World
FY2024 EPS Estimates for Zymeworks Lifted by Leerink Partnrs - MarketBeat
Analysts Update Their Estimates For Zymeworks BC Inc - Stocks Register
Q4 Earnings Estimate for Zymeworks Issued By Leerink Partnrs - Defense World
Zymeworks (NYSE:ZYME) Raised to Strong-Buy at Leerink Partnrs - Defense World
Leerink Partnrs Forecasts Zymeworks' Q4 Earnings (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking - Simply Wall St
Zymeworks (NYSE:ZYME) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat
Leerink lifts Zymeworks stock target on pipeline progress By Investing.com - Investing.com Nigeria
Leerink lifts Zymeworks stock target on pipeline progress - Investing.com
Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours - Clinical Trials Arena
Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $18.00 - Defense World
Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire
Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - The Manila Times
Zymeworks (NYSE:ZYME) Sets New 52-Week High Following Analyst Upgrade - Defense World
Zymeworks stock soars to 52-week high of $14.08 amid robust gains - Investing.com Canada
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (NYSE:ZYME) Cut to Equal Weight at Wells Fargo & Company - Defense World
Zymeworks’ (ZYME) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St
Wells Fargo Downgrades Zymeworks (ZYME) - MSN
Zymeworks (NYSE:ZYME) Shares Gap Down – Here’s What Happened - Defense World
Zymeworks Inc. (NYSE:ZYME) Q3 2024 Earnings Call Transcript - Insider Monkey
Zymeworks Q4 2024 Earnings Preview - MSN
Zymeworks to Spotlight Innovations at Investor Conferences - MSN
Earnings call: Zymeworks reports Q3 2024 results and pipeline progress - Investing.com
Zymeworks (NYSE:ZYME) Shares Gap DownHere's Why - MarketBeat
Zymeworks stock downgraded at Wells Fargo (ZYME:NASDAQ) - Seeking Alpha
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook - Simply Wall St
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year - Yahoo Finance
HC Wainwright Reiterates Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Zymeworks Inc (ZYME) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Zymeworks Reports Q3 Results and Strategic Advances - TipRanks
Zymeworks Advances Biotherapeutic Pipeline in 2024 - TipRanks
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Zymeworks Q3 2024 Earnings Preview - MSN
Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Lo - GuruFocus.com
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):